Baby Duchenne Study: Early Years in Boys With DMD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tracks development and health in young boys with Duchenne muscular dystrophy during the first three years of life. It aims to better understand early signs and how the condition progresses, which may help improve care and future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is a boy younger than 3 years old.
- Your child has a confirmed genetic change (mutation) in the DMD gene.
- Your child does not have another genetic condition that could affect early development.
- You are able to provide written permission and to follow the study schedule, including all clinic visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses remote technology, like apps or wearable devices, to monitor motor skills and development in boys with Duchenne muscular dystrophy (DMD). It aims to find better ways to measure how the disease progresses over time without requiring frequent clinic visits.
This study remotely tracks motor development in children with Duchenne muscular dystrophy or spinal muscular atrophy who were diagnosed at birth or before symptoms started. It aims to see if early monitoring helps improve long-term care and outcomes.
This study examines how different genetic changes in the DMD gene affect heart function in boys with dystrophinopathy (a muscle-weakening condition). Understanding this connection may help doctors better monitor and treat heart problems in affected boys.
This early-phase study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and helps improve muscle function in young boys.
This trial tests a new gene therapy called SPOT-03 to see if it can help the body make dystrophin, a protein that is missing in Duchenne muscular dystrophy (DMD). It is for boys ages 2 to under 8 who can still walk at least 10 meters.
This study looks at what helps or limits physical activity in children with Duchenne Muscular Dystrophy. Researchers will ask you and your child questions and have your child do simple physical tasks to understand their daily activity levels.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.